{"protocolSection": {"identificationModule": {"nctId": "NCT00635882", "orgStudyIdInfo": {"id": "P05122"}, "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)", "officialTitle": "A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti-Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents With Persistent Allergic Asthma"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-02"}, "primaryCompletionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-01-21", "studyFirstSubmitQcDate": "2008-03-07", "studyFirstPostDateStruct": {"date": "2008-03-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-10-22", "resultsFirstSubmitQcDate": "2011-01-12", "resultsFirstPostDateStruct": {"date": "2011-02-09", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2009-07-08", "dispFirstSubmitQcDate": "2009-07-15", "dispFirstPostDateStruct": {"date": "2009-10-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-08", "lastUpdatePostDateStruct": {"date": "2024-05-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a 2-week double-blind, placebo-controlled, parallel group study comparing the anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) formulation and medium dose mometasone furoate (MF) dry powder inhaler (DPI) and MDI formulations in adults and adolescents with persistent allergic asthma.", "detailedDescription": "This is a 2-week double-blind, placebo-controlled, parallel group study comparing the anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol fumarate MDI formulation and medium dose mometasone furoate (MF) DPI and MDI formulations in adults and adolescents with persistent allergic asthma. An open-label run in period is to be followed by a double-blind treatment period.\n\nA total of 90 subjects (15 per treatment) will be enrolled to ensure 12 subjects per treatment at the Day 14 evaluation, accounting for a 20% drop-out rate. A sample size of 12 subjects per treatment is required to detect a treatment difference of 28% in percent change of eNO at Day 14, assuming a pooled standard deviation of 20% with a power of 90%. These estimates are based on examination of eNO levels in asthmatic vs healthy subjects in an article written by S.A. Kharitonov et. al, 2003.\n\nSubjects will be randomized to one of six treatment groups (MF/F MDI 100/10 mcg BID, MF/F MDI 200/10 mcg BID, MF/F MDI 400/10 mcg BID, MF DPI 200 mcg BID, MF MDI 200 mcg BID, or Placebo MDI BID) according to an Schering-Plough Research Institute (SPRI) computer-generated randomization schedule. Randomization will be performed in appropriately sized blocks using random numbers generated by statistical analysis software (SAS)."}, "conditionsModule": {"conditions": ["Asthma", "Airway Inflammation"], "keywords": ["mometasone", "formoterol"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 93, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MF/F MDI 100/10 mcg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: mometasone furoate/formoterol 100/10 mcg"]}, {"label": "MF/F MDI 200/10 mcg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: mometasone furoate/formoterol 200/10 mcg"]}, {"label": "MF/F MDI 400/10 mcg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: mometasone furoate/formoterol 400/10 mcg"]}, {"label": "MF DPI 200 mcg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MF DPI 200 mcg"]}, {"label": "MF MDI 200 mcg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MF MDI 200 mcg"]}, {"label": "Placebo", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "mometasone furoate/formoterol 100/10 mcg", "description": "mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days", "armGroupLabels": ["MF/F MDI 100/10 mcg"], "otherNames": ["MF/F (SCH 418131)"]}, {"type": "DRUG", "name": "mometasone furoate/formoterol 200/10 mcg", "description": "mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days", "armGroupLabels": ["MF/F MDI 200/10 mcg"], "otherNames": ["MF/F 200/10 (SCH 418131)"]}, {"type": "DRUG", "name": "mometasone furoate/formoterol 400/10 mcg", "description": "mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days", "armGroupLabels": ["MF/F MDI 400/10 mcg"], "otherNames": ["MF/F 400/10 (SCH 418131)"]}, {"type": "DRUG", "name": "MF DPI 200 mcg", "description": "MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days", "armGroupLabels": ["MF DPI 200 mcg"], "otherNames": ["mometasone furoate (SCH 32088)"]}, {"type": "DRUG", "name": "MF MDI 200 mcg", "description": "MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days", "armGroupLabels": ["MF MDI 200 mcg"], "otherNames": ["mometasone furoate (SCH 32088)"]}, {"type": "DRUG", "name": "Placebo", "description": "MF/F MDI placebo twice daily (BID) (2 inhalations)", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Percent Change From Baseline to Day 14 in Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)", "timeFrame": "Baseline to Day 14"}], "secondaryOutcomes": [{"measure": "Mean Percent Change From Baseline to Day 7 in eNO Ppb", "timeFrame": "Baseline to Day 7"}, {"measure": "Mean Percent Change From Baseline to Day 14 in Sputum Eosinophil Count (Percentage)", "timeFrame": "Baseline to Day 14"}, {"measure": "Mean Change From Baseline to Day 15 of Mannitol Challenge", "description": "Mannitol challenge (also referred to as PD15) is the provocative dose of mannitol required to produce a 15% reduction in the forced expiratory volume (in liters) in one second (FEV1).", "timeFrame": "Baseline to Day 15"}, {"measure": "Change From Baseline in AM Total Asthma Symptom Score at Days 2-15", "description": "Twice daily, participants rated the following asthma symptoms as experienced during the time period since the last evaluation: wheezing, difficulty breathing, and cough on a scale of 0 (none) to 3 (severe, very uncomfortable and interfered with most or all of normal daily activities/sleep). The total asthma symptom score ranged from 0 to 9. The results were recorded in the participant's diary.", "timeFrame": "Baseline and Days 2-15"}, {"measure": "Change From Baseline in PM Total Asthma Symptom Score at Days 1-15", "description": "Twice daily, participants rated the following asthma symptoms as experienced during the time period since the last evaluation: wheezing, difficulty breathing, and cough on a scale of 0 (none) to 3 (severe, very uncomfortable and interfered with most or all of normal daily activities/sleep). The total asthma symptom score ranged from 0 to 9. The results were recorded in the participant's diary.", "timeFrame": "Baseline and Days 1-15"}, {"measure": "Change From Baseline in AM Peak Expiratory Flow (PEF) at Days 2-15", "timeFrame": "Baseline and Days 2-15"}, {"measure": "Change From Baseline in PM PEF at Days 1-15", "timeFrame": "Baseline and Days 1-15"}], "otherOutcomes": [{"measure": "Baseline Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)", "timeFrame": "Baseline"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* To document asthma diagnosis, historical reversibility defined as an increase in absolute forced expiratory volume (in liters) in 1 second (FEV1) of \\>= 12% and \\>= 200 mL must have been performed within 12 months of Screening. For subjects without historical reversibility, one of the following methods can be used at the Screening Visit or at any time before the Baseline Visit:\n\n  * Demonstration of an increase in absolute FEV1 of at least 12% and a volume increase of at least 200 mL within 15-20 minutes after administration of 4 inhalations of albuterol/salbutamol (total dose 360 to 400 mcg) or of nebulized short-acting beta agonist (SABA) (2.5 mg), if confirmed as standard office practice, OR\n  * Demonstration of a peak expiratory flow (PEF) variability of more than 20% expressed as a percentage of the mean highest and lowest morning prebronchodilator PEF over at least 1 week, OR\n  * Demonstration of a diurnal variation PEF of more than 20% based on the difference between the prebronchodilator (before taking albuterol/salbutamol) morning value and the postbronchodilator value (after taking albuterol/salbutamol) from the evening before, expressed as a percentage of the mean daily PEF value on any day during the open-label Run-in Period. {The calculation formula: Diurnal PEF Variation = Absolute \\[(highest of 3 readings, PM Post-bronchodilator (BD) PEF from prior evening) - (highest of 3 readings, AM Pre-BD from morning value)\\]/\\[(highest PM Post-BD + highest AM Pre-BD)/2\\] \\* 100}\n* At Screening and Baseline Visits, a subject must have persistent allergic asthma with an FEV1 \\>65% predicted.\n* A subject must be allergic to at least one common allergen (grasses, trees, weeds, house dust mites, molds, dog and cat) as demonstrated by clinical symptoms when exposed to the allergen(s), and by skin prick testing or a radioallergosorbent (RAST) class \\>1 (excluding modified RAST procedure \\[mRAST\\]) within 2 years of inclusion in the study.\n* If, based upon the medical judgment of the investigator, there is no inherent harm in changing the subject's current asthma therapy, the subject and/or parent/guardian) must agree to discontinue prescribed inhaled corticosteroid (ICS), anticholinergics, leukotriene receptor inhibitors, and long-acting beta-2 agonists at the Screening Visit as per required washouts, and be transferred to treatment with SABA for relief for 2 weeks before the Baseline/Randomization Visit.\n* Clinical laboratory tests (complete blood count, blood chemistries, and urinalysis) conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator.\n* An electrocardiogram (ECG) performed at the Screening Visit or within 30 days prior to Screening Visit must be clinically acceptable to the investigator and have a QTc interval \\<440 milliseconds for males and \\<450 msec for females.\n* At Screening or any time prior to Baseline, a subject must have an eNO level of \\>30 parts per billion (ppb) at a flow rate of 50 mL/second.\n* At Screening or any time before Baseline, a subject must have a sputum eosinophil count \\>3% of total cell count.\n* Willingness to give written informed consent and ability to adhere to dose and visit schedules. A subject 12 to 17 years of age must also provide written assent.\n* A nonpregnant female subject of childbearing potential (with a negative serum pregnancy test at Screening) must use a medically acceptable, adequate form of birth control. If not currently sexually active she must agree to use a double-barrier method if she becomes sexually active during the study.\n\nExclusion Criteria:\n\n* Use of systemic glucocorticosteroids within 3 months before Screening.\n* Upper or lower respiratory tract infection within 4 weeks before Screening.\n* Decrease in absolute FEV1 \\>20% between Screening and Baseline Visits.\n* Requirement for \\> 8 inhalations per day of SABA MDI, or 2 or more nebulized treatments of 2.5 mg SABA, on any 2 consecutive days between the Screening and Baseline Visits.\n* A decrease in AM or PM PEF below the Run-in Period stability limit on any 2 consecutive days before Baseline. At Visit 1, the Run-in Period stability limit for PEF will be established based on the subject's personal best. If the subject does not have a historical personal best, the historical PEF measurement will be the PEF predicted based on the subject's sex, age, and height. PEF value to be multiplied by 0.70 to determine stability limit.\n* A clinical asthma exacerbation defined as a clinical deterioration of asthma that results in emergency treatment, hospitalization for asthma, or treatment with additional, excluded asthma medication (including oral or other systemic corticosteroids but allowing SABA), as per investigator, between Screening and Baseline Visits.\n* Inability to induce sputum after 1 or 2 trys.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "referencesModule": {"references": [{"pmid": "23490226", "type": "DERIVED", "citation": "Nolte H, Pavord I, Backer V, Spector S, Shekar T, Gates D, Nair P, Hargreave F. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma. Respir Med. 2013 May;107(5):656-64. doi: 10.1016/j.rmed.2013.02.010. Epub 2013 Mar 13."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "FG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "FG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "FG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "FG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "FG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "12"}, {"groupId": "FG003", "numSubjects": "15"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "13"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "12"}, {"groupId": "FG003", "numSubjects": "15"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "13"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "BG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "BG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "BG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "BG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "BG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}, {"id": "BG006", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "15"}, {"groupId": "BG004", "value": "16"}, {"groupId": "BG005", "value": "13"}, {"groupId": "BG006", "value": "93"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "18 to <65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "15"}, {"groupId": "BG004", "value": "16"}, {"groupId": "BG005", "value": "11"}, {"groupId": "BG006", "value": "87"}]}]}, {"title": "> or = to 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "2"}, {"groupId": "BG006", "value": "6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "6"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "47"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "10"}, {"groupId": "BG005", "value": "5"}, {"groupId": "BG006", "value": "46"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Percent Change From Baseline to Day 14 in Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)", "populationDescription": "All Randomized Participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of eNO", "timeFrame": "Baseline to Day 14", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "OG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "OG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "OG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "OG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "OG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "14"}, {"groupId": "OG004", "value": "15"}, {"groupId": "OG005", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-35.3", "spread": "40.3"}, {"groupId": "OG001", "value": "-45.4", "spread": "40.3"}, {"groupId": "OG002", "value": "-61.4", "spread": "40.3"}, {"groupId": "OG003", "value": "-51.3", "spread": "40.3"}, {"groupId": "OG004", "value": "-46.1", "spread": "40.3"}, {"groupId": "OG005", "value": "0.1", "spread": "40.3"}]}]}], "analyses": [{"groupIds": ["OG002", "OG005"], "groupDescription": "Analysis of covariance (ANCOVA) model with treatment and baseline eNO as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline eNO as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.003", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG000", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline eNO as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.018", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Mean Percent Change From Baseline to Day 7 in eNO Ppb", "populationDescription": "All Randomized Participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of eNO", "timeFrame": "Baseline to Day 7", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "OG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "OG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "OG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "OG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "OG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "14"}, {"groupId": "OG004", "value": "15"}, {"groupId": "OG005", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-37.9", "spread": "36.3"}, {"groupId": "OG001", "value": "-39.7", "spread": "36.3"}, {"groupId": "OG002", "value": "-45.6", "spread": "36.3"}, {"groupId": "OG003", "value": "-46.0", "spread": "36.3"}, {"groupId": "OG004", "value": "-37.2", "spread": "36.3"}, {"groupId": "OG005", "value": "4.8", "spread": "36.3"}]}]}], "analyses": [{"groupIds": ["OG002", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline eNO as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline eNO as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.002", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG000", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline eNO as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.002", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Mean Percent Change From Baseline to Day 14 in Sputum Eosinophil Count (Percentage)", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Sputum Eosinophil Count", "timeFrame": "Baseline to Day 14", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "OG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "OG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "OG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "OG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "OG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "12"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.1", "spread": "127.6"}, {"groupId": "OG001", "value": "-35.5", "spread": "127.6"}, {"groupId": "OG002", "value": "-75.4", "spread": "127.6"}, {"groupId": "OG003", "value": "-55.3", "spread": "127.6"}, {"groupId": "OG004", "value": "-33.7", "spread": "127.6"}, {"groupId": "OG005", "value": "71.7", "spread": "127.6"}]}]}], "analyses": [{"groupIds": ["OG002", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline eosinophils as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline EOS as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.024", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline eosinophils as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline EOS as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.051", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG000", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline eosinophils as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline EOS as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.336", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to Day 15 of Mannitol Challenge", "description": "Mannitol challenge (also referred to as PD15) is the provocative dose of mannitol required to produce a 15% reduction in the forced expiratory volume (in liters) in one second (FEV1).", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "milligrams", "timeFrame": "Baseline to Day 15", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "OG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "OG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "OG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "OG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "OG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "8"}, {"groupId": "OG004", "value": "9"}, {"groupId": "OG005", "value": "9"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "102.2", "spread": "106.7"}, {"groupId": "OG001", "value": "48.6", "spread": "106.7"}, {"groupId": "OG002", "value": "67.9", "spread": "106.7"}, {"groupId": "OG003", "value": "137.6", "spread": "106.7"}, {"groupId": "OG004", "value": "126.0", "spread": "106.7"}, {"groupId": "OG005", "value": "159.4", "spread": "106.7"}]}]}, {"title": "Mean Change from Baseline to Day 15", "categories": [{"measurements": [{"groupId": "OG000", "value": "176.6", "spread": "264"}, {"groupId": "OG001", "value": "153.8", "spread": "264"}, {"groupId": "OG002", "value": "162.9", "spread": "264"}, {"groupId": "OG003", "value": "159.4", "spread": "264"}, {"groupId": "OG004", "value": "146.2", "spread": "264"}, {"groupId": "OG005", "value": "-63.7", "spread": "264"}]}]}], "analyses": [{"groupIds": ["OG002", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline PD15 as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline PD15 as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.120", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Day 15."}, {"groupIds": ["OG001", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline PD15 as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline PD15 as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.103", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Day 15."}, {"groupIds": ["OG000", "OG005"], "groupDescription": "ANCOVA model with treatment and baseline PD15 as a covariate was used.\n\nStandard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline PD15 as a covariate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.048", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Day 15."}]}, {"type": "SECONDARY", "title": "Change From Baseline in AM Total Asthma Symptom Score at Days 2-15", "description": "Twice daily, participants rated the following asthma symptoms as experienced during the time period since the last evaluation: wheezing, difficulty breathing, and cough on a scale of 0 (none) to 3 (severe, very uncomfortable and interfered with most or all of normal daily activities/sleep). The total asthma symptom score ranged from 0 to 9. The results were recorded in the participant's diary.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Days 2-15", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "OG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "OG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "OG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "OG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "OG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "16"}, {"groupId": "OG005", "value": "13"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.6", "spread": "1.66"}, {"groupId": "OG001", "value": "1.2", "spread": "1.66"}, {"groupId": "OG002", "value": "2.2", "spread": "1.66"}, {"groupId": "OG003", "value": "1.5", "spread": "1.66"}, {"groupId": "OG004", "value": "1.1", "spread": "1.66"}, {"groupId": "OG005", "value": "1.4", "spread": "1.66"}]}]}, {"title": "Mean Change from Baseline to Days 2-15", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "1.28"}, {"groupId": "OG001", "value": "-0.7", "spread": "1.28"}, {"groupId": "OG002", "value": "-1.5", "spread": "1.28"}, {"groupId": "OG003", "value": "-1.2", "spread": "1.28"}, {"groupId": "OG004", "value": "-0.5", "spread": "1.28"}, {"groupId": "OG005", "value": "-0.2", "spread": "1.28"}]}]}], "analyses": [{"groupIds": ["OG002", "OG005"], "groupDescription": "One-way analysis of variance (ANOVA) model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.018", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 2-15."}, {"groupIds": ["OG001", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.261", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 2-15."}, {"groupIds": ["OG000", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.334", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 2-15."}]}, {"type": "SECONDARY", "title": "Change From Baseline in PM Total Asthma Symptom Score at Days 1-15", "description": "Twice daily, participants rated the following asthma symptoms as experienced during the time period since the last evaluation: wheezing, difficulty breathing, and cough on a scale of 0 (none) to 3 (severe, very uncomfortable and interfered with most or all of normal daily activities/sleep). The total asthma symptom score ranged from 0 to 9. The results were recorded in the participant's diary.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Days 1-15", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "OG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "OG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "OG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "OG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "OG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "15"}, {"groupId": "OG005", "value": "13"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "spread": "1.62"}, {"groupId": "OG001", "value": "1.1", "spread": "1.62"}, {"groupId": "OG002", "value": "2.1", "spread": "1.62"}, {"groupId": "OG003", "value": "1.6", "spread": "1.62"}, {"groupId": "OG004", "value": "1.6", "spread": "1.62"}, {"groupId": "OG005", "value": "1.7", "spread": "1.62"}]}]}, {"title": "Mean Change from Baseline to Days 1-15", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "1.24"}, {"groupId": "OG001", "value": "-0.6", "spread": "1.24"}, {"groupId": "OG002", "value": "-1.4", "spread": "1.24"}, {"groupId": "OG003", "value": "-1.1", "spread": "1.24"}, {"groupId": "OG004", "value": "-0.7", "spread": "1.24"}, {"groupId": "OG005", "value": "-0.3", "spread": "1.24"}]}]}], "analyses": [{"groupIds": ["OG002", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.037", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 1-15."}, {"groupIds": ["OG001", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.643", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 1-15."}, {"groupIds": ["OG000", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.963", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 1-15."}]}, {"type": "SECONDARY", "title": "Change From Baseline in AM Peak Expiratory Flow (PEF) at Days 2-15", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters/minute", "timeFrame": "Baseline and Days 2-15", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "OG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "OG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "OG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "OG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "OG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "16"}, {"groupId": "OG005", "value": "13"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "452.6", "spread": "112.1"}, {"groupId": "OG001", "value": "421.2", "spread": "112.1"}, {"groupId": "OG002", "value": "468.7", "spread": "112.1"}, {"groupId": "OG003", "value": "466.3", "spread": "112.1"}, {"groupId": "OG004", "value": "473.3", "spread": "112.1"}, {"groupId": "OG005", "value": "413.2", "spread": "112.1"}]}]}, {"title": "Mean Change from Baseline to Days 2-15", "categories": [{"measurements": [{"groupId": "OG000", "value": "48.1", "spread": "47.0"}, {"groupId": "OG001", "value": "46.9", "spread": "47.0"}, {"groupId": "OG002", "value": "69.8", "spread": "47.0"}, {"groupId": "OG003", "value": "30.3", "spread": "47.0"}, {"groupId": "OG004", "value": "30.8", "spread": "47.0"}, {"groupId": "OG005", "value": "-9.0", "spread": "47.0"}]}]}], "analyses": [{"groupIds": ["OG002", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 2-15."}, {"groupIds": ["OG001", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.002", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 2-15."}, {"groupIds": ["OG000", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 2-15."}]}, {"type": "SECONDARY", "title": "Change From Baseline in PM PEF at Days 1-15", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters/minute", "timeFrame": "Baseline and Days 1-15", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "OG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "OG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "OG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "OG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "OG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "15"}, {"groupId": "OG005", "value": "13"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "462.0", "spread": "114.6"}, {"groupId": "OG001", "value": "437.2", "spread": "114.6"}, {"groupId": "OG002", "value": "486.7", "spread": "114.6"}, {"groupId": "OG003", "value": "484.4", "spread": "114.6"}, {"groupId": "OG004", "value": "472.5", "spread": "114.6"}, {"groupId": "OG005", "value": "422.7", "spread": "114.6"}]}]}, {"title": "Mean Change from Baseline to Days 1-15", "categories": [{"measurements": [{"groupId": "OG000", "value": "47.7", "spread": "42.3"}, {"groupId": "OG001", "value": "34.5", "spread": "42.3"}, {"groupId": "OG002", "value": "66.8", "spread": "42.3"}, {"groupId": "OG003", "value": "20.2", "spread": "42.3"}, {"groupId": "OG004", "value": "28.3", "spread": "42.3"}, {"groupId": "OG005", "value": "4.5", "spread": "42.3"}]}]}], "analyses": [{"groupIds": ["OG002", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 1-15."}, {"groupIds": ["OG001", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.057", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 1-15."}, {"groupIds": ["OG000", "OG005"], "groupDescription": "One-way ANOVA model with treatment effect was used.\n\nStandard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.005", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis applies to Mean Change from Baseline to Days 1-15."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Baseline Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ppb", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg", "description": "Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days"}, {"id": "OG001", "title": "MF/F MDI 200/10 mcg", "description": "MF/F MDI 200/10 mcg BID for 14 days"}, {"id": "OG002", "title": "MF/F MDI 400/10 mcg", "description": "MF/F MDI 400/10 mcg BID for 14 days"}, {"id": "OG003", "title": "MF DPI 200 mcg", "description": "Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days"}, {"id": "OG004", "title": "MF MDI 200 mcg", "description": "MF MDI 200 mcg BID for 14 days"}, {"id": "OG005", "title": "Placebo", "description": "Placebo MDI BID for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "14"}, {"groupId": "OG004", "value": "15"}, {"groupId": "OG005", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.8", "spread": "40.8"}, {"groupId": "OG001", "value": "70.0", "spread": "40.8"}, {"groupId": "OG002", "value": "77.1", "spread": "40.8"}, {"groupId": "OG003", "value": "102.6", "spread": "40.8"}, {"groupId": "OG004", "value": "66.2", "spread": "40.8"}, {"groupId": "OG005", "value": "79.6", "spread": "40.8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "MF/F MDI 100/10 MCG BID", "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 2, "otherNumAtRisk": 20}, {"id": "EG001", "title": "MF/F MDI 200/10 MCG BID", "seriousNumAffected": 0, "seriousNumAtRisk": 17, "otherNumAffected": 8, "otherNumAtRisk": 17}, {"id": "EG002", "title": "MF/F MDI 400/10 MCG BID", "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 1, "otherNumAtRisk": 12}, {"id": "EG003", "title": "MF DPI 200 MCG BID", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 2, "otherNumAtRisk": 15}, {"id": "EG004", "title": "MF MDI 200 MCG BID", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 6, "otherNumAtRisk": 16}, {"id": "EG005", "title": "PLACEBO", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 2, "otherNumAtRisk": 13}], "otherEvents": [{"term": "EAR DISCOMFORT", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "GASTROOESOPHAGEAL REFLUX DISEASE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "INGUINAL HERNIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "PYREXIA", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "ORAL CANDIDIASIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "SPINAL CORD INJURY", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "SUNBURN", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "DIZZINESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 3, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "DRY THROAT", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "DYSPHONIA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "NASAL CONGESTION", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "OROPHARYNGEAL PAIN", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "RHINITIS ALLERGIC", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "THROAT IRRITATION", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "PAIN OF SKIN", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "PRURITUS", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The investigator agrees not to publish/present any interim results without prior\n\nsponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada", "Denmark", "Germany", "Sweden", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000007249", "term": "Inflammation"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10293", "name": "Inflammation", "asFound": "Inflammation", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068656", "term": "Mometasone Furoate"}, {"id": "D000068759", "term": "Formoterol Fumarate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M290", "name": "Mometasone Furoate", "asFound": "Tea", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}